• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Zachary Jennifer was granted 7,768 shares, increasing direct ownership by 54% to 22,064 units (SEC Form 4)

    6/3/25 4:33:55 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RGNX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Zachary Jennifer

    (Last) (First) (Middle)
    C/O REGENXBIO INC.
    9804 MEDICAL CENTER DRIVE

    (Street)
    ROCKVILLE MD 20850

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    REGENXBIO Inc. [ RGNX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/30/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/30/2025 A 7,768(1) A $0.00 22,064 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Options (Right to Buy) $8.85 05/30/2025 A 39,815 (2) 05/30/2035 Common Stock 39,815 $0.00 39,815 D
    Explanation of Responses:
    1. Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 1, 2026 subject to the continuous service of the recipient to the Issuer.
    2. The option will vest in 12 equal monthly installments following May 30, 2025 subject to the continuous service of the optionee to the Issuer.
    Remarks:
    /s/ Patrick J. Christmas as attorney-in-fact 06/03/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $RGNX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RGNX

    DatePrice TargetRatingAnalyst
    2/11/2025$38.00 → $14.00Buy → Neutral
    Goldman
    2/7/2025$27.00Outperform
    Raymond James
    11/15/2024$22.00Overweight
    Morgan Stanley
    10/10/2024$18.00Outperform
    Raymond James
    6/7/2024$38.00Buy
    Goldman
    3/11/2024$36.00Buy
    H.C. Wainwright
    3/8/2024$20.00 → $35.00Sector Perform → Outperform
    RBC Capital Mkts
    3/6/2024$37.00Market Perform → Outperform
    Leerink Partners
    More analyst ratings

    $RGNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

      SC 13G/A - REGENXBIO Inc. (0001590877) (Subject)

      11/14/24 9:00:57 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

      SC 13G/A - REGENXBIO Inc. (0001590877) (Subject)

      11/12/24 4:47:45 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

      SC 13G/A - REGENXBIO Inc. (0001590877) (Subject)

      11/4/24 1:49:56 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGNX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

      RGX-202 demonstrating consistent evidence of positively changing disease trajectory for Duchenne All dose level 2 participants exceeded external natural history controls on all functional measuresBiomarker data demonstrate consistent, robust microdystrophin expression and transduction levels across all treated ages One new participant aged 2 years at dosing had expression level at 118.6% compared to controlFavorable safety profile continues with no serious adverse events or adverse events of special interest observed Webcast to be held at 8:00 a.m. todayROCKVILLE, Md., June 5, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced new positive interim data from the Phase I/II AFFI

      6/5/25 7:05:00 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202

      Event will feature Aravindhan Veerapandiyan, M.D., principal investigator of the AFFINITY DUCHENNE® trialROCKVILLE, Md., June 2, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a webcast to discuss new interim functional data from the Phase I/II AFFINITY DUCHENNE® trial of RGX-202, the company's next-generation investigational gene therapy for the treatment of Duchenne muscular dystrophy. The webcast will feature AFFINITY DUCHENNE principal investigator Aravindhan Veerapandiyan, M.D., Arkansas Children's Hospital. Webcast detailsTitle: AFFINITY DUCHENNE® Trial of RGX-202: Phase I/II Interim Functional DataDate/Time: Thursday, June 5, 2025, at 8:00 a.m. EDT

      6/2/25 7:05:00 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

      $150 million secured at closing extends cash runway into early 2027REGENXBIO retains additional potential non-dilutive funding opportunities, including monetization of Priority Review Voucher (PRV) and milestones from AbbVie ROCKVILLE, Md., May 19, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced the closure of a non-dilutive, limited recourse royalty bond agreement of up to $250 million with Healthcare Royalty (HCRx). This agreement monetizes select anticipated royalties and milestones, and provides both immediate and expected future, non-dilutive capital.  REGENXBIO received $150 million at closing, extending the Company's expected cash runway into early 2027. "This strate

      5/19/25 4:05:00 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Fox Allan M. was granted 7,768 shares, increasing direct ownership by 69% to 19,054 units (SEC Form 4)

      4 - REGENXBIO Inc. (0001590877) (Issuer)

      6/3/25 4:37:11 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Zachary Jennifer was granted 7,768 shares, increasing direct ownership by 54% to 22,064 units (SEC Form 4)

      4 - REGENXBIO Inc. (0001590877) (Issuer)

      6/3/25 4:33:55 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Tasse Daniel was granted 7,768 shares, increasing direct ownership by 69% to 19,054 units (SEC Form 4)

      4 - REGENXBIO Inc. (0001590877) (Issuer)

      6/3/25 4:33:32 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGNX
    SEC Filings

    See more
    • REGENXBIO Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - REGENXBIO Inc. (0001590877) (Filer)

      6/3/25 4:30:27 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • REGENXBIO Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - REGENXBIO Inc. (0001590877) (Filer)

      5/19/25 4:15:15 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by REGENXBIO Inc.

      144 - REGENXBIO Inc. (0001590877) (Subject)

      5/12/25 4:29:06 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGNX
    Leadership Updates

    Live Leadership Updates

    See more
    • Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, Dec. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t

      12/6/24 6:29:00 PM ET
      $AMTM
      $APO
      $CMA
      $CRI
      Investment Managers
      Finance
      Major Banks
      Apparel
    • REGENXBIO Appoints Mitchell Chan as Chief Financial Officer

      Life sciences veteran Mitchell Chan joins the company ahead of multiple catalysts across late-stage gene therapy programsVit Vasista steps down following more than 15 years at the CompanyROCKVILLE, Md., Sept. 17, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that Mitchell Chan has been appointed as Executive Vice President and Chief Financial Officer, effective today. A veteran finance executive and operating partner in the biotechnology industry, Mr. Chan has held key roles in raising capital, business development transactions and operations for nearly 20 years.  "We are excited to welcome Mitchell at this exciting time for REGENXBIO," said Curran Simpson, President and

      9/17/24 7:05:00 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • REGENXBIO Announces Leadership Transition

      Curran Simpson, Chief Operating Officer, Appointed as President and CEOCo-Founder Kenneth T. Mills to Step Down as President and CEO; Named Chairman of the Board ROCKVILLE, Md., June 12, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that Curran Simpson, Chief Operating Officer, has been appointed as President, Chief Executive Officer and a member of the Board of Directors, effective July 1, 2024. Co-Founder Kenneth T. Mills will step down as President and Chief Executive Officer following 15 years of leadership at the Company, and he is taking on an expanded role on the Board as Chairman. In connection with these changes, Board member Daniel Tassé has been appointed as RE

      6/12/24 7:05:00 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGNX
    Financials

    Live finance-specific insights

    See more
    • REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights

      RGX-202 in Duchenne muscular dystrophy on track for BLA submission mid-2026Pivotal trial more than half enrolled, with completion expected in 2025 Additional Phase I/II functional data expected 1H 2025 Initiating commercial supply manufacturing in Q3 2025FDA acceptance of Biologics License Application (BLA) for clemidsogene lanparvovec (RGX-121, partnered with Nippon Shinyaku) expected in May 2025 Pivotal data evaluating the safety and efficacy of the subretinal delivery of surabgene lomparvovec (ABBV-RGX-314, partnered with AbbVie) in patients with wet age-related macular degeneration are expected in 2026 and planning of diabetic retinopathy pivotal study continuesConference call today at 4

      5/12/25 4:05:00 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights

      ROCKVILLE, Md., April 30, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Monday, May 12, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2025, and recent operational highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mi

      4/30/25 4:05:00 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

      ROCKVILLE, Md., Feb. 26, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Thursday, March 13, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2024, and recent operational highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc.REGENXBIO is a leading

      2/26/25 4:05:00 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • REGENXBIO downgraded by Goldman with a new price target

      Goldman downgraded REGENXBIO from Buy to Neutral and set a new price target of $14.00 from $38.00 previously

      2/11/25 7:12:20 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James resumed coverage on REGENXBIO with a new price target

      Raymond James resumed coverage of REGENXBIO with a rating of Outperform and set a new price target of $27.00

      2/7/25 8:29:59 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Morgan Stanley resumed coverage on REGENXBIO with a new price target

      Morgan Stanley resumed coverage of REGENXBIO with a rating of Overweight and set a new price target of $22.00

      11/15/24 8:17:57 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care